Héctor Jausàs | Life Sciences Partner | Fieldfisher Spain | Fieldfisher
Skip to main content
Professional background

Professional background

I have extensive knowledge of the legal challenges faced by the pharmaceutical industry in regulatory matters (pricing and reimbursement), advertising, competition law, commercial contracts, data protection, and product liability.

I advise national and international companies in the pharmaceutical, healthcare, cosmetics, and food sectors.

I have been a member of Conférence Bleue since 1997 and served as co-directing partner from 2012 to 2021. I am a member of the Real Academia de Farmacia de Cataluña and a guest lecturer at European Union conferences at the Universidad Carlos III de Madrid, as well as a speaker at the summer courses of the Universidad de Navarra.

I currently advise over 50 national and international companies in the pharmaceutical, healthcare, cosmetics, and food sectors on a regular basis.

I lead the Life Sciences Department at Fieldfisher Spain, which is recognised by Chambers & Partners as one of the leading practices in this field. Chambers & Partners also highlights me as a leading lawyer in regulatory and competition law.

Chambers & Partners has also ranked me as a leading lawyer in Spain for regulatory and competition law (Band 1) in Life Sciences

Since 2005, I have been consistently recognised by Chambers & Partners as a leading lawyer in Life Sciences in Spain.

I am annually recognised by Best Lawyers as one of the top lawyers in my field and was named Best Lawyer of the Year in 2014 and 2016. 

In 2007, I received the 40 Under Forty award from the prestigious international publication Iberian Lawyer for my track record in Commercial and Pharmaceutical Law.

Awards & recognition

Awards & recognition

Héctor Jausàs is a strong pillar in his team as he has a strategic and commercial vision.

Chambers and Partners

Héctor Jausàs stands out for his world on contentious mandates in the Spanish life sciences sector. He regulary advises multinational pharmaceuticals on regulatory, competition and contractual issues. 

Chambers and Partners

Authored pieces

All Resources
A gloved scientist uses a pipette to add liquid to a 96-well plate in a laboratory. Scientific equipment and a computer screen displaying chemical formulas are visible in the background, highlighting a research environment.
Life Sciences
Insight

The EU Biotech Act: From Regulatory Reform to Business Action

24.06.2026
Learn more
Close-up of a laboratory setting featuring a plastic test tube rack and graduated pipettes submerged in water with bubbles surrounding them. The background transitions from pink to blue tones, creating a visually appealing scientific scene.
Life Sciences
Insight

The European Court of Justice opens the way for chemically synthesised generics of reference biological medicinal products

29.04.2026
Learn more
Close-up of several blister packs filled with blue and white capsules. The capsules are arranged in a grid-like pattern, and the lighting highlights some of the rows, giving a metallic sheen to the packaging.
Life Sciences
Insight

The European Court of Justice issues a landmark decision concerning defective medicines, facilitating patient indemnification

27.03.2026
Learn more
Several packs of pills in various shapes and colors are scattered on a surface. The medication is contained in blister packs, with some capsules being half white and half blue, others in different color combinations. The image uses blue and pink lighting.
Life Sciences
Insight

Potential new financial sanctions in France for innovative pharmaceutical companies delaying the launch of generics

23.01.2026
Learn more
Press Release

Fieldfisher Spain reports 18% revenue growth, driven by international expansion and cross-selling

12.03.2025
Fieldfisher Spain has reported a remarkable 18% increase in revenue, reaching €16.3 million in 2024, with the financial year running from January to December. The success highlights the firm's strong financial performance and its ambitious growth strategy. This year's financial results surpass the firm’s 2023–2025 strategic plan, which set a 35% growth target over the period and a 20% revenue increase for 2024.
Learn more